Finance

Beta
Lists
ENTBF:OTCMKTS
Entheon Biomedical Corp
USD 0,035
0,00%
(0,00) 1D
8 Jul., 14:04:30 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ENTBF...
Mkt. cap
970,13 k
Avg. vol.
313,00
Volume
0,00
52-wk high
USD 0,10
52-wk low
USD 0,00
Beta
2,43
Shares outstanding
13,86 m
No. of employees
1
Mkt. cap
970,13 k
Avg. vol.
313,00
Volume
0,00
52-wk high
USD 0,10
52-wk low
USD 0,00
Beta
2,43
Shares outstanding
13,86 m
No. of employees
1
News stories
From sources across the web
About Entheon Biomedical Corp
CEO-
Employees1
FoundedJun. 2019
HeadquartersVancouver, Brits-Columbië, Kanada
Sector-
Websiteentheonbiomedical.com
Previous reportsAll values in CAD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CAD
Mei 2025
Aug. 2025
Nov. 2025
Feb. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
66,09 k
49,93 k
66,50 k
89,06 k
Operating expense
68,80 k
49,93 k
66,50 k
89,06 k
Total operating expenses
68,80 k
49,93 k
66,50 k
89,06 k
Operating income
-68,80 k
-49,93 k
-66,50 k
-89,06 k
Other non operating income
-
-
-
-11,96 k
EBT including unusual items
-66,50 k
-47,11 k
-65,01 k
-99,72 k
EBT excluding unusual items
-66,50 k
-47,11 k
-65,01 k
-99,72 k
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-66,50 k
-47,11 k
-65,01 k
-99,72 k
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
2,31 k
2,82 k
1,56 k
1,29 k
Interest expense
-
-
-
-
Net interest expenses
2,31 k
2,82 k
1,56 k
1,29 k
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer